International Journal of Cardiovascular Imaging (@intjcvimaging) 's Twitter Profile
International Journal of Cardiovascular Imaging

@intjcvimaging

We are passionate about teaching cardiovascular imaging to the medical community!

ID: 1171956148452413441

calendar_today12-09-2019 01:18:46

1,1K Tweet

671 Followers

337 Following

Carlos G Santos-Gallego, MD (@santosgallegomd) 's Twitter Profile Photo

“If you want to go fast, go alone If you want to go far, go with your team” This is the best team for heart function/failure in the world Such a great night celebrating the holiday party of our Heart Failure team Mount Sinai Fuster Heart Hospital 🎄🕎 Merry Christmas! חנוכה שמח Chag Urim Sameach!

“If you want to go fast, go alone
If you want to go far, go with your team”
This is the best team for heart function/failure in the world
Such a great night celebrating the holiday party of our Heart Failure team <a href="/MountSinaiHeart/">Mount Sinai Fuster Heart Hospital</a> 🎄🕎
Merry Christmas!
חנוכה שמח
Chag Urim Sameach!
International Journal of Cardiovascular Imaging (@intjcvimaging) 's Twitter Profile Photo

Great editorial comment about the CLEAR Outcomes trial by the world-renown lipid expert Juanbadimon As we are an imaging journal, this trial could only be better if it also had imaging endpoints! #whyCMR #yesCCT #echofirst

Carlos G Santos-Gallego, MD (@santosgallegomd) 's Twitter Profile Photo

Breaking news: FDA has just approved sotagliflozin (brand name "Inpefa") for Treatment of Heart Failure!!!! Broad label across full LVEF range (HFpEF&HFrEF), and for patients with or without T2DM First dual SGLT1/2 inhibitor to be approved in HF Dr. Deepak L. Bhatt Christos Argyropoulos MD PhD FlozinatorInChief🇺🇸

Breaking news: FDA has just approved sotagliflozin (brand name "Inpefa") for Treatment of Heart Failure!!!!

Broad label across full LVEF range (HFpEF&amp;HFrEF), and for patients with or without T2DM

First dual SGLT1/2 inhibitor to be approved in HF

<a href="/DLBHATTMD/">Dr. Deepak L. Bhatt</a> <a href="/ChristosArgyrop/">Christos Argyropoulos MD PhD FlozinatorInChief🇺🇸</a>
Carlos G Santos-Gallego, MD (@santosgallegomd) 's Twitter Profile Photo

Proud to present tomorrow the latest evidence at #ADA2023 about SGLT2i and heart failure. Best panel ever with my friends Darren McGuire (discussing SGLT2i/GLP1RA) and Pam R. Taub, MD❤️💃🏻 (discussing GLP-1RA in CVD), moderated by Om Ganda Dr. Deepak L. Bhatt GoggleDocs adameetingnews.org/live-updates/s…

Proud to present tomorrow the latest evidence at #ADA2023 about SGLT2i and heart failure. 
Best panel ever with my friends Darren McGuire (discussing SGLT2i/GLP1RA) and <a href="/PamTaubMD/">Pam R. Taub, MD❤️💃🏻</a> (discussing GLP-1RA in CVD), moderated by <a href="/gandaom/">Om Ganda</a>
<a href="/DLBHATTMD/">Dr. Deepak L. Bhatt</a> <a href="/GoggleDocs/">GoggleDocs</a> 
adameetingnews.org/live-updates/s…
International Journal of Cardiovascular Imaging (@intjcvimaging) 's Twitter Profile Photo

That is a hefty cut!! Efficacy of SGLT2i on HF demonstrated both clinically and using imaging. For imaging studies in HF, please read International Journal of Cardiovascular Imaging #echofirst #whyCMR #yesCCT #cardioed #meded

International Journal of Cardiovascular Imaging (@intjcvimaging) 's Twitter Profile Photo

Do not miss this session! Carlos G Santos-Gallego, MD uses imaging to evaluate the effect of therapies, both for HFrEF and for HFpEF If you want to learn more about imaging, ready our journal International Journal of Cardiovascular Imaging #cardioed #meded #echofirst #yesCCT #whyCMR

International Journal of Cardiovascular Imaging (@intjcvimaging) 's Twitter Profile Photo

What a great moment to be working in HFpEF specifically and cardiometabolism in general! Wanna learn how to evaluate HFpEF using imaging? Read our journal International Journal of Cardiovascular Imaging #echofirst #yesCCT #whyCMR

Carlos G Santos-Gallego, MD (@santosgallegomd) 's Twitter Profile Photo

It is my honor and my privilege to be a Discussant for the Late-Breaking Clinical Trial Session editorializing the SOUL trial Oral semaglutide ⬇️3P-MACE by 14% in T2DM with CVD and/or CKD. Plus improvement in PAD events too Dr. Deepak L. Bhatt Anu Lala-Trindade Mount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai

It is my honor and my privilege to be a Discussant for the Late-Breaking Clinical Trial Session editorializing the SOUL trial
Oral semaglutide ⬇️3P-MACE by 14% in T2DM with CVD and/or CKD. Plus improvement in PAD events too
<a href="/DLBHATTMD/">Dr. Deepak L. Bhatt</a> <a href="/dranulala/">Anu Lala-Trindade</a> <a href="/MountSinaiHeart/">Mount Sinai Fuster Heart Hospital</a> <a href="/IcahnMountSinai/">Icahn School of Medicine at Mount Sinai</a>
Carlos G Santos-Gallego, MD (@santosgallegomd) 's Twitter Profile Photo

One of the best lectures I have ever attended! Only Elazar Edelman can mix together endothelium, quantum physics, history, philosophy, determinism vs heuristics, through the lens of modernism Love the reenactment of the famous image of Laennec auscultation! (2nd photo) Dr. Deepak L. Bhatt

One of the best lectures I have ever attended! Only Elazar Edelman can mix together endothelium, quantum physics, history, philosophy, determinism vs heuristics, through the lens of modernism
Love the reenactment of the famous image of Laennec auscultation! (2nd photo) <a href="/DLBHATTMD/">Dr. Deepak L. Bhatt</a>
International Journal of Cardiovascular Imaging (@intjcvimaging) 's Twitter Profile Photo

Groundbreaking work that Elazer Edelman is doing in endothelium and biomaterials using imaging as endpoint If you want to know more about CV imaging, follow us and read our articles! International Journal of Cardiovascular Imaging #echofirst #yescct #whyCMR